{
  "id": "everyday#risk_safety_1cea2a58",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "Contents Acknowledgements v Abbreviations vii Glossary ix Executive summary xvii 1. Introduction 2 1.1 Background and rationale 2 1.2 Aims and objectives 3 1.3 Target audience 3 1.4 Scope of the guideline 3 2. Methods 4 2.1 Contributors to the guideline 4 2.2 Declaration of interests 5 2.3 Identifying, appraising and synthesizing available evidence 5 2.4 Decision-making during the GDG meetings 9 2.5 Document preparation and peer review 9 3. Recommendations 11 3.1 Alcohol use disorders (ALC) 12 3.2 Anxiety (ANX) 18 3.3 Child and adolescent mental disorders (CAMH) 28 3.4 Conditions related to stress (STR) 46 3.5 Dementia (DEM) 50 3.6 Depression (DEP) 58 3.7 Drug use disorders (DRU) 64 3.8 Epilepsy and seizures (EPI) 76 3.9 Overarching areas (OVE) 86 3.10 Psychosis and bipolar disorder (PSY) 88 3.11 Self-harm and suicide (SUI) 108 iii Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 4. Publication 112 4.1 Publication and dissemination of the guideline 112 4.2 Derivative products 112 4.3 WHO model list of essential medicines (EML) 112 5. Monitoring and evaluating the impact of the guideline 113 6. Updating the evidence 114 References 115 Annex 1. Contributors to the guideline 130 Annex 2. Managing declarations of interest and conflicts of interest 145 Evidence profiles are available at: https://www.who.int/teams/mental-health-and-substance-use/treatment-care/ mental-health-gap-action-programme/evidence-centre iv",
  "gloss_vi": "Contents acknowledgements v abbreviations vii glossary ix executive summary xvii 1. introduction 2 1.1 background and rationale 2 1.2 aims and objectives 3 1.3 target audience 3 1.4 scope of the guideline 3 2.",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "referral"
    ],
    "life_topics": [
      "stress",
      "relationships",
      "grief"
    ],
    "advice_section": [
      "work_habits"
    ],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn Contents Acknowledgements v Abbreviations vii Glossary ix Executive summary xvii 1. Introduction 2 1.1 Background and rationale 2 1.2 Aims and objectives 3 1.3 Target audience 3 1.4 Scope of the guideline 3 2. Methods 4 2.1 Contributors to the guideline 4 2.2 Declaration of interests 5 2.3 Identifying, appraising and synthesizing available evidence 5 2.4 Decision-making during the GDG meetings 9 2.5 Document preparation and peer review 9 3. Recommendations 11 3.1 Alcohol use disorders (ALC) 12 3.2 Anxiety (ANX) 18 3.3 Child and adolescent mental disorders (CAMH) 28 3.4 Conditions related to stress (STR) 46 3.5 Dementia (DEM) 50 3.6 Depression (DEP) 58 3.7 Drug use disorders (DRU) 64 3.8 Epilepsy and seizures (EPI) 76 3.9 Overarching areas (OVE) 86 3.10 Psychosis and bipolar disorder (PSY) 88 3.11 Self-harm and suicide (SUI) 108 iii Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 4. Publication 112 4.1 Publication and dissemination of the guideline 112 4.2 Derivative products 112 4.3 WHO model list of essential medicines (EML) 112 5. Monitoring and evaluating the impact of the guideline 113 6. Updating the evidence 114 References 115 Annex 1. Contributors to the guideline 130 Annex 2. Managing declarations of interest and conflicts of interest 145 Evidence profiles are available at: https://www.who.int/teams/mental-health-and-substance-use/treatment-care/ mental-health-gap-action-programme/evidence-centre iv Contents acknowledgements v abbreviations vii glossary ix executive summary xvii 1. introduction 2 1.1 background and rationale 2 1.2 aims and objectives 3 1.3 target audience 3 1.4 scope of the guideline 3 2."
}